Novavax ((NVAX)) announced an update on their ongoing clinical study.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Novavax is conducting a study titled A Randomized, Observer-Blinded, Active-Controlled Study to Evaluate the Safety and Immunogenicity of a COVID-19 Influenza Combination Nanoparticle Vaccine and a Standalone Trivalent Nanoparticle Influenza Hemagglutinin Vaccine in Participants ≥ 65 Years of Age. The study aims to assess the safety and immune response of a new combination vaccine for COVID-19 and influenza compared to a standard flu vaccine in older adults. This research is significant as it could lead to a more efficient vaccination strategy for these diseases.
The study tests a combination vaccine (CIC) that includes components for both COVID-19 and influenza, as well as standalone vaccines for COVID-19 and influenza. The goal is to determine if the combination vaccine can effectively protect against both illnesses.
This is a Phase 3 interventional study with a randomized, crossover design. Participants and researchers are unaware of which vaccine is administered to ensure unbiased results. The primary purpose is prevention, focusing on vaccine safety and immune response.
The study began on December 9, 2024, with a primary completion date yet to be announced. The most recent update was submitted on July 16, 2025. These dates are crucial for tracking the study’s progress and anticipating results.
For investors, this study could impact Novavax’s stock performance, especially if the combination vaccine proves effective. Successful results may enhance investor confidence and position Novavax competitively in the vaccine market, particularly against other companies developing similar vaccines.
The study is ongoing, and further details can be found on the ClinicalTrials portal.